DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Patent 6,703,396 protects BIKTARVY, SYMTUZA, EMTRIVA, ATRIPLA, COMPLERA, DESCOVY, GENVOYA, ODEFSEY, STRIBILD, and TRUVADA, and is included in eleven NDAs.
Protection for EMTRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and seventy-six patent family members in thirty-four countries.
Summary for Patent: 6,703,396
|Title:||Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers|
|Abstract:||A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.|
|Inventor(s):||Liotta; Dennis C. (Stone Mountain, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)|
|Assignee:||Emory University (Atlanta, GA)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 6,703,396|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use; Dosage form;|
Foreign Priority and PCT Information for Patent: 6,703,396
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|